BrainStorm Cell Therapeutics Inc. announced a partnership with Pluri Inc. to support the manufacturing of its NurOwn cellular therapy for an upcoming Phase 3b trial targeting amyotrophic lateral sclerosis (ALS). The agreement, established through a Memorandum of Understanding (MOU), allows
Pluri Inc., a biotechnology company, has signed a tech transfer and manufacturing agreement with Kadimastem Ltd., a clinical stage biotechnology company developing therapeutic cells for ALS and diabetes treatments. The agreement involves PluriCDMO, which was launched earlier this year and leverages
Pluri Inc., a biotechnology firm based in Haifa, Israel, recently announced the launch of two new business verticals. These are PluriAgtech and PluriCDMO, aimed at leveraging its cell-based technology in agriculture and providing contract development and manufacturing services, respectively. The company’s
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
